Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FBIO - US34960Q3074 - Common Stock

4.2 USD
-0.1 (-2.33%)
Last: 1/12/2026, 8:00:02 PM
4.49 USD
+0.29 (+6.9%)
After Hours: 1/12/2026, 8:00:02 PM
Fundamental Rating

2

FBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. FBIO may be in some trouble as it scores bad on both profitability and health. FBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

FBIO had negative earnings in the past year.
FBIO had a negative operating cash flow in the past year.
FBIO had negative earnings in each of the past 5 years.
FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of FBIO (-2.94%) is better than 86.93% of its industry peers.
FBIO's Return On Equity of -9.55% is amongst the best of the industry. FBIO outperforms 87.88% of its industry peers.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

FBIO's Gross Margin of 71.56% is amongst the best of the industry. FBIO outperforms 82.39% of its industry peers.
In the last couple of years the Gross Margin of FBIO has declined.
The Profit Margin and Operating Margin are not available for FBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

2

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
FBIO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FBIO has been increased compared to 5 years ago.
The debt/assets ratio for FBIO is higher compared to a year ago.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.92, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
FBIO has a Altman-Z score of -5.92. This is in the lower half of the industry: FBIO underperforms 63.26% of its industry peers.
A Debt/Equity ratio of 0.86 indicates that FBIO is somewhat dependend on debt financing.
The Debt to Equity ratio of FBIO (0.86) is worse than 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -5.92
ROIC/WACCN/A
WACC9.9%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

FBIO has a Current Ratio of 2.19. This indicates that FBIO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.19, FBIO is not doing good in the industry: 73.86% of the companies in the same industry are doing better.
FBIO has a Quick Ratio of 1.97. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of FBIO (1.97) is worse than 74.24% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.37%, which is quite impressive.
Looking at the last year, FBIO shows a decrease in Revenue. The Revenue has decreased by -0.32% in the last year.
Measured over the past years, FBIO shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

Based on estimates for the next years, FBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.48% on average per year.
Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 64.44% on average per year.
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.89%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (1/12/2026, 8:00:02 PM)

After market: 4.49 +0.29 (+6.9%)

4.2

-0.1 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-24 2026-03-24/amc
Inst Owners15.2%
Inst Owner Change-7.88%
Ins Owners14.3%
Ins Owner Change1.66%
Market Cap130.37M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target10.97 (161.19%)
Short Float %14.62%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)0%
PT rev (3m)-2.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.49%
EPS NY rev (1m)0%
EPS NY rev (3m)20.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.09
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 4.79
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -5.92
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC / FBIO FAQ

What is the fundamental rating for FBIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to FBIO.


Can you provide the valuation status for FORTRESS BIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to FORTRESS BIOTECH INC (FBIO). This can be considered as Overvalued.


Can you provide the profitability details for FORTRESS BIOTECH INC?

FORTRESS BIOTECH INC (FBIO) has a profitability rating of 2 / 10.


Can you provide the financial health for FBIO stock?

The financial health rating of FORTRESS BIOTECH INC (FBIO) is 2 / 10.


Can you provide the expected EPS growth for FBIO stock?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC (FBIO) is expected to grow by 80.35% in the next year.